Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 829

1.

Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4.

Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Yang SM, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK.

Mol Cancer Ther. 2018 Nov 12. pii: molcanther.0365.2018. doi: 10.1158/1535-7163.MCT-18-0365. [Epub ahead of print]

PMID:
30420565
2.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.

Salcedo MP, Sood AK, Dos Reis R, Ramalingam P, Chen C, Frumovitz M, Jhingran A, Pitcher B, Ramirez PT, Schmeler KM.

Gynecol Oncol. 2018 Nov 2. pii: S0090-8258(18)31318-0. doi: 10.1016/j.ygyno.2018.10.035. [Epub ahead of print]

PMID:
30396690
3.

Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.

Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND.

Gynecol Oncol. 2018 Oct 23. pii: S0090-8258(18)31299-X. doi: 10.1016/j.ygyno.2018.10.017. [Epub ahead of print]

PMID:
30366647
4.

PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.

Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2018 Oct 10. pii: molcanther.1050.2017. doi: 10.1158/1535-7163.MCT-17-1050. [Epub ahead of print]

PMID:
30305341
5.

Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers.

Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, Fan Y, Xu X, Morgan MA, Long M, Zhang Y, Zhang R, Sood AK, Rebbeck TR, Dang CV, Zhang L.

Cancer Cell. 2018 Oct 8;34(4):549-560.e9. doi: 10.1016/j.ccell.2018.08.019.

PMID:
30300578
6.

Bone protection by inhibition of microRNA-182.

Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, Sood AK, Zhao L, Zhao B.

Nat Commun. 2018 Oct 5;9(1):4108. doi: 10.1038/s41467-018-06446-0.

7.

A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.

Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN.

Gynecol Oncol. 2018 Nov;151(2):374-380. doi: 10.1016/j.ygyno.2018.08.037. Epub 2018 Sep 10. Review.

PMID:
30213435
8.

Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer.

Zhang L, Peng D, Sood AK, Dang CV, Zhong X.

Mol Cancer Ther. 2018 Sep;17(9):1816-1823. doi: 10.1158/1535-7163.MCT-18-0124. Review.

PMID:
30181330
9.

CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.

Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, Wi TI, Lee JM, Kang TH, Jung ID, Cho YJ, Ahn HJ, Shin BC, Lee YJ, Sood AK, Han HD, Park YM.

Cancer Res. 2018 Nov 1;78(21):6247-6256. doi: 10.1158/0008-5472.CAN-17-3871. Epub 2018 Aug 16.

PMID:
30115698
10.

Bioactive lipid metabolism in platelet "first responder" and cancer biology.

Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG.

Cancer Metastasis Rev. 2018 Sep;37(2-3):439-454. doi: 10.1007/s10555-018-9755-8.

PMID:
30112590
11.

Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.

Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK.

Obstet Gynecol. 2018 Sep;132(3):545-554. doi: 10.1097/AOG.0000000000002796.

PMID:
30095787
12.

Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.

Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC Jr.

Clin Cancer Res. 2018 Oct 15;24(20):5072-5084. doi: 10.1158/1078-0432.CCR-18-0504. Epub 2018 Jul 3.

PMID:
30084832
13.

FABP4 as a key determinant of metastatic potential of ovarian cancer.

Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK.

Nat Commun. 2018 Jul 26;9(1):2923. doi: 10.1038/s41467-018-04987-y.

14.

Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis.

Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, López JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler H.

Res Pract Thromb Haemost. 2018 Apr 12;2(3):407-428. doi: 10.1002/rth2.12095. eCollection 2018 Jul. Review.

15.

When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System.

Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK.

Int J Gynecol Cancer. 2018 Oct;28(8):1485-1490. doi: 10.1097/IGC.0000000000001329.

PMID:
30036226
16.

Tunable terahertz photoconductivity of hydrogen functionalized graphene using optical pump-terahertz probe spectroscopy.

Kar S, Mohapatra DR, Sood AK.

Nanoscale. 2018 Aug 7;10(29):14321-14330. doi: 10.1039/c8nr04154g. Epub 2018 Jul 18.

PMID:
30020299
17.

Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.

González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martín-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, García MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, Sánchez-Rovira P, Chang JC, Granados-Principal S.

Clin Cancer Res. 2018 Jul 16. doi: 10.1158/1078-0432.CCR-17-3125. [Epub ahead of print]

PMID:
30012564
18.

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

Dal Molin GZ, Omatsu K, Sood AK, Coleman RL.

Ther Adv Med Oncol. 2018 Jun 22;10:1758835918778483. doi: 10.1177/1758835918778483. eCollection 2018. Review.

19.

Stress effects on FosB and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.

Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK.

J Biol Chem. 2018 Jun 29;293(26):10041. doi: 10.1074/jbc.AAC118.004299. No abstract available.

20.

Stress, inflammation, and eicosanoids: an emerging perspective.

Umamaheswaran S, Dasari SK, Yang P, Lutgendorf SK, Sood AK.

Cancer Metastasis Rev. 2018 Sep;37(2-3):203-211. doi: 10.1007/s10555-018-9741-1.

PMID:
29948328

Supplemental Content

Loading ...
Support Center